- More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities; urgent need for therapeutic strategies to prevent COVID-19 in this vulnerable population   - First-of-its-kind study will enroll up to 2,400 residents and staff at long-term care facilities; will utilize

- Revenue in the second quarter of 2020 declined 2 percent, comprised of volume growth of 6 percent, a 7 percent decrease in realized prices and a 1 percent unfavorable impact from foreign exchange rates.   - The estimated negative impact of the COVID-19 pandemic on Q2 2020 revenue included

- Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction   - Treatment of heart failure is an

New Alzheimer's disease blood test could enable early diagnosis and advance understanding of how disease impacts those living with it INDIANAPOLIS , July 28, 2020 /PRNewswire/ -- A new study on Lilly 's blood test for Alzheimer's disease (AD), P-tau217 (phosphorylated tau at threonine-217), was

Highlights include data that advance the understanding of Alzheimer's disease across the spectrum including early and accurate detection, diagnosis and treatment INDIANAPOLIS , July 21, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that new results from 17 research studies

INDIANAPOLIS , July 17, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2020 financial results on Thursday, July 30, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's

- Mirikizumab met the primary and all key secondary endpoints versus placebo at Week 16 and all key secondary endpoints versus Cosentyx® (secukinumab) at Week 16 and Week 52, including superiority in skin clearance at Week 52   - Lilly will submit data from OASIS-1 and 2 to regulatory authorities

INDIANAPOLIS , July 15, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable September 10, 2020 , to shareholders of record at the close of

The fund, established by the Eli Lilly and Company Foundation, Lumina Foundation and Central Indiana Community Foundation, will focus on solutions that address racial inequities in the criminal justice system INDIANAPOLIS , June 25, 2020 /PRNewswire/ -- A coalition of local stakeholders has

Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies INDIANAPOLIS , June 24, 2020 /PRNewswire/ -- About 34 million Americans live with diabetes, and